Stockreport

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Syndax Pharmaceuticals, Inc.  (SNDX) 
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.syndax.com
PDF – First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM [Read more]